GLTO

#11856
Damora Therapeutics, Inc. Common Stock
28.69 USD
-0.76%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
28.69
28.69
Intervallo Annuale
2.01
38.33
Variazione giornaliera
-0.76%
Variazione Mensile
-6.00%
Variazione di 6 mesi
+917.38%
Variazione Annuale
+613.68%
Chiusura Precedente
28.91
Apertura
28.69
Bid
Ask
Minimo
28.69
High
28.69
Volume
10
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 1.59 B
  • Employee 7
  • Founded 2011
  • CEO Hans T. Schambye
  • Website www.damoratx.com
  • Headquarter Delaware, United States
  • FIGI BBG00XMLGWC5
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-5.78
Rapporto prezzo/fatturato
28.96

Galecto Inc

Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark. The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need.

Notizie